Kezar Life Sciences to Participate in Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upcoming virtual investor conferences. The details of the presentations are as follows:

Wells Fargo 2020 Virtual Biotech Conference
Fireside Chat: Thursday, September 10, 2020, 1:20pm EDT
Presenters: John Fowler, Chief Executive Officer; Noreen Henig, MD, Chief Medical Officer, Christopher Kirk, PhD, Chief Scientific Officer

H.C. Wainwright 22nd Annual Global Investment Conference
Presentation: Monday, September 14, 2020, 4:30pm EDT
Presenter: Celia Economides, SVP, Strategy and External Affairs

The fireside chat and presentation will be webcast live and may be accessed on the “Events & Presentations” section of the Company’s website at Kezar Life Sciences will maintain an archived replay of the webcasts on its website for 90 days after the conference.

About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction, and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company's protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.

Celia Economides

Source: Kezar Life Sciences, Inc.